3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
55
Lung Neoplasms
22
Neoplasms
4
Neoplasm Metastasis
3
Carcinoma
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Hematologic Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Stage IB-IIIA Non-small Cell Lung Carcinoma
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Rectal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)
1
Non Small Cell Lung Cancer Metastatic
1
NSCLC
1
Multiple Endocrine Neoplasia Type 2a
1
Mesothelioma
1
Interventions
pembrolizumab
1
osimertinib
1
cemiplimab
1
Vascular Endothelial Growth Factor A
1
Paroxetine
1
Paclitaxel
1
Itraconazole
1
Docetaxel
1
Carboplatin
1
Antibodies, Bispecific
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lethal Congenital Contracture Syndrome 2
×
osimertinib
×
90 days
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled